Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18-65 years, male or female~2. Conforms to diagnosis standard of chronic hepatitis B according to2005 Guideline for Prevention and Treatment of Hepatitis B, (with positive HBsAg for more than 6 months), and HBV-DNA more than 100000 copies/ml;HBeAg (+),HBsAb(-); Alanine aminotransferase（ALT） within 2 to 10 times of ULN (upper limit of normal)~3. HLA-A2 positive~4. Compensatory liver disease having following hematological and biochemical indicators:WBC≥3.5E+9/L; ANC≥1.5E+9/L; PLT≥80E+9/L; Hb≥110g/L; TBil≤1.5ULN; ALB ≥ lower limit of normal value; BUN (Urea)≤upper limit of normal value; Cr≤upper limit of normal value; prothrombin time(PT) elongation≤3 sec; Activated partial thromboplastin time（APTT） within normal value; Fasting blood glucose≤7.0mmol/L~5. TSH within normal value~6. AFP ≤20ng/ml~7. Uses effective contraception for subject with child-bearing potential (including females and female partners of males)~8. Understands and signs ICF approved by EC~9. Willing to comply with the study procedures and complete the study~Exclusion Criteria:~1. Antibody of HAV IgM, HCV, HDV IgM or HEV IgM is positive~2. Antibody of CMV IgM, EBV IgM or HIV is positive~3. Antinuclear antibody titer\>1:160~4. Hepatocarcinoma, suspected hepatocarcinoma or hepatic cirrhosis~5. Has any of the following illnesses or has a severe disease inappropriate for participation in the study based on the investigator's judgment, such as: Cardiovascular system: instable or significant cardiovascular illness such as angina pectoris, heart attack of myocardial infarction, congestive heart failure, severe hypertension, significant arrhythmia or abnormal ECG etc.; Respiratory system: bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, respiratory failure, etc.; Endocrine, metabolism diseases: diabetes mellitus, uncontrolled thyroid diseases, etc.; Others: autoimmune disorder, active tuberculosis, malignancies (e.g.tumor), neuropathic or metal illness history,etc.~6. Has used anti-HBV drug (Interferon, Lamivudine, Adefovir Dipivoxil, Entecavir and Telbivudine) and immunomodulator (Thymic peptide,etc ) 6 months prior to the administration of study medication~7. Has participated in any other drug clinical investigations within the past 3 months~8. Has allergy habitus or has suspected allergy to study drug~9. Female who is in pregnancy, in lactation or planning to become pregnant during the course of the study~10. Has a history of alcohol abuse (Alcohol consumption for more than 5 years, with daily consumption over 40g for males and over 20g for females) and known drug dependence~11. Has a history of organ transplant (except external corneal transplantation and hair transplantation)~12. Any other factors inappropriate for enrollment in the study or study completion in the view of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- εPA-44 900μg (Type: EXPERIMENTAL): Inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28.
- εPA-44 600μg+Placebo 300μg (Type: EXPERIMENTAL): Inject εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.
- Placebo 900μg (Type: PLACEBO_COMPARATOR): Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete